triple g retatrutide Retatrutide: The Triple-G Shot You'll Hear About New weight-loss drug rivaling bariatric

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE -/- mice

Inhibition of SGLT-1 in the small intestine causes more glucose transport to the distal intestine and colon, resulting in greater fermentation of glucose to SCFAs by luminal bacteria and increased sustained release of GLP-1 in the distal intestine [174] (Fig

Side effects tend to be more noticeable during this phase because your body is adjusting to rising concentrations

Since the medication also contributes to weight loss, both drugs were later released as Wegovy and Zepbound to help people with obesity